nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

29.06.2019 | Original Article

European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma

verfasst von: David Taïeb, Rodney J. Hicks, Elif Hindié, Benjamin A. Guillet, Anca Avram, Pietro Ghedini, Henri J. Timmers, Aaron T. Scott, Saeed Elojeimy, Domenico Rubello, Irène J. Virgolini, Stefano Fanti, Sona Balogova, Neeta Pandit-Taskar, Karel Pacak

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Diverse radionuclide imaging techniques are available for the diagnosis, staging, and follow-up of phaeochromocytoma and paraganglioma (PPGL). Beyond their ability to detect and localise the disease, these imaging approaches variably characterise these tumours at the cellular and molecular levels and can guide therapy. Here we present updated guidelines jointly approved by the EANM and SNMMI for assisting nuclear medicine practitioners in not only the selection and performance of currently available single-photon emission computed tomography and positron emission tomography procedures, but also the interpretation and reporting of the results.

Methods

Guidelines from related fields and relevant literature have been considered in consultation with leading experts involved in the management of PPGL. The provided information should be applied according to local laws and regulations as well as the availability of various radiopharmaceuticals.

Conclusion

Since the European Association of Nuclear Medicine 2012 guidelines, the excellent results obtained with gallium-68 (⁶⁸Ga)-labelled somatostatin analogues (SSAs) in recent years have simplified the imaging approach for PPGL patients that can also be used for selecting patients for peptide receptor radionuclide therapy as a potential alternative or complement to the traditional theranostic approach with iodine-123 (¹²³I)/iodine-131 (¹³¹I)-labelled meta-iodobenzylguanidine. Genomic characterisation of subgroups with differing risk of lesion development and subsequent metastatic spread is refining the use of molecular imaging in the personalised approach to hereditary PPGL patients for detection, staging, and follow-up surveillance.

Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915–42.CrossRefPubMed

Lloyd RV, Osamura RY, Kloppel G, Rosai JWHO. Classification of Tumours of Endocrine Organs. Lyon: IARC Press; 2017.

Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumours. Eur J Endocrinol. 2016;175:G1–G34.CrossRefPubMed

Crona J, Taieb D, Pacak K. New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. Endocr Rev. 2017;38:489–515.CrossRefPubMedPubMedCentral

Jafri M, Whitworth J, Rattenberry E, Vialard L, Kilby G, Kumar AV, et al. Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma. Clin Endocrinol. 2013;78:898–906.CrossRef

Neumann HP, Erlic Z, Boedeker CC, Rybicki LA, Robledo M, Hermsen M, et al. Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res. 2009;69:3650–6.CrossRefPubMed

Papathomas TG, Gaal J, Corssmit EP, Oudijk L, Korpershoek E, Heimdal K, et al. Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumours in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis. Eur J Endocrinol. 2014;170:1–12.CrossRefPubMed

Pasini B, McWhinney SR, Bei T, Matyakhina L, Stergiopoulos S, Muchow M, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet. 2008;16:79–88.CrossRefPubMed

Casey RT, Warren AY, Martin JE, Challis BG, Rattenberry E, Whitworth J, et al. Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumour Association Syndrome (RAPTAS): Case Series and Literature Review. J Clin Endocrinol Metab. 2017;102:4013–22.CrossRefPubMedPubMedCentral

10.

Eisenhofer G, Pacak K, Huynh TT, Qin N, Bratslavsky G, Linehan WM, et al. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer. 2011;18:97–111.CrossRefPubMed

11.

Hannah-Shmouni F, Pacak K, Stratakis CA. Metanephrines for Evaluating Palpitations and Flushing. JAMA. 2017;318:385–6. CrossRefPubMedPubMedCentral

12.

Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab. 2003;88:2656–66.CrossRefPubMed

13.

Leung K, Stamm M, Raja A, Low G. Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging. AJR Am J Roentgenol. 2013;200:370–8.CrossRefPubMed

14.

Canu L, Van Hemert JAW, Kerstens MN, Hartman RP, Khanna A, Kraljevic I, et al. CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. J Clin Endocrinol Metab. 2019;104:312–8.CrossRefPubMed

15.

Turkova H, Prodanov T, Maly M, Martucci V, Adams K, Widimsky J, Jr., et al. Characteristics and outcomes of metastatic SDHB and sporadic pheochromocytoma/paraganglioma: An National Institutes of Health Study. 2016;22:302–14.

16.

Hescot S, Curras-Freixes M, Deutschbein T, van Berkel A, Vezzosi D, Amar L, et al. European Network for the Study of Adrenal Tumours (ENS@T). Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumours Retrospective Study. J Clin Endocrinol Metab. 2019;104:2367–74.CrossRefPubMed

17.

Crona J, Lamarca A, Ghosal S, Welin S, Skogseid B, Pacak K. Genotype-phenotype correlations in pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2019. https://doi.org/10.1530/ERC-19-0024.

18.

Fishbein L, Khare S, Wubbenhorst B, DeSloover D, D’Andrea K, Merrill S, et al. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nat Commun. 2015;6:6140.CrossRefPubMed

19.

Zelinka T, Musil Z, Duskova J, Burton D, Merino MJ, Milosevic D, et al. Metastatic pheochromocytoma: does the size and age matter? Eur J Clin Investig. 2011;41:1121–8.CrossRef

20.

Eisenhofer G, Lenders JW, Siegert G, Bornstein SR, Friberg P, Milosevic D, et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer. 2012;48:1739–49.CrossRefPubMed

21.

Kong G, Schenberg T, Yates CJ, Trainer A, Sachithanandan N, Iravani A, et al. The role of 68Ga-DOTA-Octreotate (GaTate) PET/CT in follow-up of SDH-associated pheochromocytoma and paraganglioma (PPGL). J Clin Endocrinol Metab. 2019. https://doi.org/10.1210/jc.2019-00018.

22.

Heimburger C, Veillon F, Taieb D, Goichot B, Riehm S, Petit-Thomas J, et al. Head-to-head comparison between 18F-FDOPA PET/CT and MR/CT angiography in clinically recurrent head and neck paragangliomas. Eur J Nucl Med Mol Imaging. 2017;44:979–87.CrossRefPubMed

23.

Kong G, Grozinsky-Glasberg S, Hofman MS, Callahan J, Meirovitz A, Maimon O, et al. Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. J Clin Endocrinol Metab. 2017;102:3278–87.CrossRefPubMed

24.

Rutgers M, Tytgat GA, Verwijs-Janssen M, Buitenhuis C, Voute PA, Smets LA. Uptake of the neuron-blocking agent meta-iodobenzylguanidine and serotonin by human platelets and neuro-adrenergic tumour cells. Int J Cancer. 1993;54:290–5.CrossRefPubMed

25.

Jaques S Jr, Tobes MC, Sisson JC. Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one. Cancer Res. 1987;47:3920–8.PubMed

26.

Bomanji J, Levison DA, Flatman WD, Horne T, Bouloux PM, Ross G, et al. Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: a histopathological comparison. J Nucl Med. 1987;28:973–8.PubMed

27.

ICRP. Radiation Dose to Patients from Radiopharmaceuticals. ICRP Publication 53. Ann IRCP. 1988;18.

28.

Sinclair AJ, Bomanji J, Harris P, Ross G, Besser GM, Britton KE. Pre- and post-treatment distribution pattern of 123I-MIBG in patients with phaeochromocytomas and paragangliomas. Nucl Med Commun. 1989;10:567–76.CrossRefPubMed

29.

Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun. 1992;13:513–21.CrossRefPubMed

30.

Jacobson AF, Travin MI. Impact of medications on mIBG uptake, with specific attention to the heart: Comprehensive review of the literature. J Nucl Cardiol. 2015;22:980–93.CrossRefPubMed

31.

Jacobson AF, White S, Travin MI, Tseng C. Impact of concomitant medication use on myocardial 123I-mIBG imaging results in patients with heart failure. Nucl Med Commun. 2017;38:141–8.CrossRefPubMed

32.

Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, et al. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:2436–46.CrossRefPubMed

33.

Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, et al. 131I/123I-metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2003;30:BP132–9.PubMed

34.

Bar-Sever Z, Biassoni L, Shulkin B, Kong G, Hofman MS, Lopci E, et al. Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging. 2018.

35.

Khafagi FA, Shapiro B, Fig LM, Mallette S, Sisson JC. Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med. 1989;30:481–9.PubMed

36.

Apeldoorn L, Voerman HJ, Hoefnagel CA. Interference of MIBG uptake by medication: a case report. Neth J Med. 1995;46:239–43.CrossRefPubMed

37.

Estorch M, Carrio I, Mena E, Flotats A, Camacho V, Fuertes J, et al. Challenging the neuronal MIBG uptake by pharmacological intervention: effect of a single dose of oral amitriptyline on regional cardiac MIBG uptake. Eur J Nucl Med Mol Imaging. 2004;31:1575–80.CrossRefPubMed

38.

Zaplatnikov K, Menzel C, Dobert N, Hamscho N, Kranert WT, Gotthard M, et al. Case report: drug interference with MIBG uptake in a patient with metastatic paraganglioma. Br J Radiol. 2004;77:525–7.CrossRefPubMed

39.

Blake GM, Lewington VJ, Fleming JS, Zivanovic MA, Ackery DM. Modification by nifedipine of 131I-meta-iodobenzylguanidine kinetics in malignant phaeochromocytoma. Eur J Nucl Med. 1988;14:345–8.PubMed

40.

Taniguchi K, Ishizu K, Torizuka T, Hasegawa S, Okawada T, Ozawa T, et al. Metastases of predominantly dopamine-secreting phaeochromocytoma that did not accumulate meta-iodobenzylguanidine: imaging with whole body positron emission tomography using 18F-labelled deoxyglucose. Eur J Surg. 2001;167:866–70.CrossRefPubMed

41.

Van Der Horst-Schrivers AN, Osinga TE, Kema IP, Van Der Laan BF, Dullaart RP. Dopamine excess in patients with head and neck paragangliomas. Anticancer Res. 2010;30:5153–8.

42.

van Gelder T, Verhoeven GT, de Jong P, Oei HY, Krenning EP, Vuzevski VD, et al. Dopamine-producing paraganglioma not visualized by iodine-123-MIBG scintigraphy. J Nucl Med. 1995;36:620–2.PubMed

43.

Hall FT, Perez-Ordonez B, Mackenzie RG, Gilbert RW. Does Catecholamine Secretion from Head and Neck Paragangliomas Respond to Radiotherapy? Case Report and Literature Review. Skull Base. 2003;13:229–34.CrossRefPubMedPubMedCentral

44.

Ishibashi N, Abe K, Furuhashi S, Fukushima S, Yoshinobu T, Takahashi M, et al. Adverse allergic reaction to 131I MIBG. Ann Nucl Med. 2009;23:697–9.CrossRefPubMed

45.

ICRP. Radiation dose to patients from radiopharmaceuticals. Addendum 2 to ICRP Publication 53. Ann IRCP. 1998;28:1–126.

46.

Tobes MC, Fig LM, Carey J, Geatti O, Sisson JC, Shapiro B. Alterations of iodine-131 MIBG biodistribution in an anephric patient: comparison to normal and impaired renal function. J Nucl Med. 1989;30:1476–82.PubMed

47.

Friedman NC, Hassan A, Grady E, Matsuoka DT, Jacobson AF. Efficacy of thyroid blockade on thyroid radioiodine uptake in 123I-mIBG imaging. J Nucl Med. 2014;55:211–5.CrossRefPubMed

48.

Beauregard JM, Hofman MS, Pereira JM, Eu P, Hicks RJ. Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. Cancer Imaging. 2011;11:56–66.CrossRefPubMedPubMedCentral

49.

Tran-Gia J, Lassmann M. Characterization of Noise and Resolution for Quantitative (177)Lu SPECT/CT with xSPECT Quant. J Nucl Med. 2019;60:50–9.CrossRefPubMed

50.

Bailey DL, Willowson KP. Quantitative SPECT/CT: SPECT joins PET as a quantitative imaging modality. Eur J Nucl Med Mol Imaging. 2014;41(Suppl 1):S17–25.CrossRefPubMed

51.

Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, et al. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumours causing catecholamine excess. J Clin Endocrinol Metab. 2009;94:3922–30.CrossRefPubMed

52.

Fonte JS, Robles JF, Chen CC, Reynolds J, Whatley M, Ling A, et al. False-negative (1)(2)(3)I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocr Relat Cancer. 2012;19:83–93.CrossRefPubMedPubMedCentral

53.

Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Lazurova I, et al. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med. 2008;49:1613–9.CrossRefPubMed

54.

Timmers HJ, Eisenhofer G, Carrasquillo JA, Chen CC, Whatley M, Ling A, et al. Use of 6-[18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO). Clin Endocrinol. 2009;71:11–7.CrossRef

55.

Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94:4757–67.CrossRefPubMedPubMedCentral

56.

Eisenhofer G, Rivers G, Rosas AL, Quezado Z, Manger WM, Pacak K. Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management. Drug Saf. 2007;30:1031–62.CrossRefPubMed

57.

Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H, et al. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumours. Radiology. 2001;220:373–80.CrossRefPubMed

58.

Kaji P, Carrasquillo JA, Linehan WM, Chen CC, Eisenhofer G, Pinto PA, et al. The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol. 2007;156:483–7.CrossRefPubMed

59.

Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, et al. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab. 2010;95:2800–10.CrossRefPubMed

60.

King KS, Chen CC, Alexopoulos DK, Whatley MA, Reynolds JC, Patronas N, et al. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab. 2011;96:2779–85.CrossRefPubMedPubMedCentral

61.

Rufini V, Treglia G, Castaldi P, Perotti G, Calcagni ML, Corsello SM, et al. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma. Nucl Med Commun. 2011;32:575–82.CrossRefPubMed

62.

Taieb D, Tessonnier L, Sebag F, Niccoli-Sire P, Morange I, Colavolpe C, et al. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clin Endocrinol. 2008;69:580–6.CrossRef

63.

Janssen I, Chen CC, Taieb D, Patronas NJ, Millo CM, Adams KT, et al. 68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. J Nucl Med. 2016;57:186–91.CrossRefPubMed

64.

Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, de Jong M, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med. 1992;33:652–8.PubMed

65.

Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:1441–8.CrossRefPubMed

66.

Balon HR, Brown TL, Goldsmith SJ, Silberstein EB, Krenning EP, Lang O, et al. The SNM practice guideline for somatostatin receptor scintigraphy 2.0. J Nucl Med Technol. 2011;39:317–24.CrossRefPubMed

67.

ICRP. Radiation Dose to Patients fromRadiopharmaceuticals: A Compendium of Current Information Related to Frequently Used Substances. ICRP Publication 128. Ann IRCP. 2015:44.

68.

Balon HR. Updated practice guideline for somatostatin receptor scintigraphy. J Nucl Med. 2011;52:1838.CrossRefPubMed

69.

Bustillo A, Telischi F, Weed D, Civantos F, Angeli S, Serafini A, et al. Octreotide scintigraphy in the head and neck. Laryngoscope. 2004;114:434–40.CrossRefPubMed

70.

Duet M, Sauvaget E, Petelle B, Rizzo N, Guichard JP, Wassef M, et al. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med. 2003;44:1767–74.PubMed

71.

Koopmans KP, Jager PL, Kema IP, Kerstens MN, Albers F, Dullaart RP. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med. 2008;49:1232–7.CrossRefPubMed

72.

Muros MA, Llamas-Elvira JM, Rodriguez A, Ramirez A, Gomez M, Arraez MA, et al. 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma. Nucl Med Commun. 1998;19:735–42.CrossRefPubMed

73.

Schmidt M, Fischer E, Dietlein M, Michel O, Weber K, Moka D, et al. Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas. Eur J Nucl Med Mol Imaging. 2002;29:1571–80.CrossRefPubMed

74.

Telischi FF, Bustillo A, Whiteman ML, Serafini AN, Reisberg MJ, Gomez-Marin O, et al. Octreotide scintigraphy for the detection of paragangliomas. Otolaryngol Head Neck Surg. 2000;122:358–62.CrossRefPubMed

75.

Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, Hignette C, Hernigou A, Halimi P, et al. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab. 2013;98:E162–73.CrossRefPubMed

76.

Kaltsas GA, Mukherjee JJ, Grossman AB. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours. Ann Oncol. 2001;12(Suppl 2):S47–50.CrossRefPubMed

77.

van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, et al. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001;86:685–93.PubMed

78.

Tenenbaum F, Lumbroso J, Schlumberger M, Mure A, Plouin PF, Caillou B, et al. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med. 1995;36:1–6.PubMed

79.

Wild D, Macke HR, Waser B, Reubi JC, Ginj M, Rasch H, et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005;32:724.CrossRefPubMed

80.

Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338–47.CrossRefPubMed

81.

Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–82.CrossRefPubMed

82.

Fani M, Nicolas GP, Wild D. Somatostatin Receptor Antagonists for Imaging and Therapy. J Nucl Med. 2017;58:61S–6S.CrossRefPubMed

83.

Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:72–9.CrossRefPubMed

84.

Cherk MH, Kong G, Hicks RJ, Hofman MS. Changes in biodistribution on (68)Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression. Cancer Imaging. 2018;18:3.CrossRefPubMedPubMedCentral

85.

Sandstrom M, Velikyan I, Garske-Roman U, Sorensen J, Eriksson B, Granberg D, et al. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumours. J Nucl Med. 2013;54:1755–9.CrossRefPubMed

86.

Aalbersberg EA, de Wit-van der Veen BJ, Versleijen MWJ, Saveur LJ, Valk GD, Tesselaar MET, et al. Influence of lanreotide on uptake of (68)Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation. Eur J Nucl Med Mol Imaging. 2019;46:696–703.CrossRefPubMed

87.

Lasnon C, Hicks RJ, Beauregard JM, Milner A, Paciencia M, Guizard AV, et al. Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer. Clin Nucl Med. 2012;37:971–6.CrossRefPubMed

88.

Castellucci P, Pou Ucha J, Fuccio C, Rubello D, Ambrosini V, Montini GC, et al. Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J Nucl Med. 2011;52:886–90.CrossRefPubMed

89.

Archier A, Varoquaux A, Garrigue P, Montava M, Guerin C, Gabriel S, et al. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. Eur J Nucl Med Mol Imaging. 2016;43:1248–57.CrossRefPubMed

90.

Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35:500–16.CrossRefPubMed

91.

Naji M, Al-Nahhas A. (68)Ga-labelled peptides in the management of neuroectodermal tumours. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 1):S61–7.CrossRefPubMed

92.

Naji M, Zhao C, Welsh SJ, Meades R, Win Z, Ferrarese A, et al. 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol. 2011;13:769–75.CrossRefPubMed

93.

Sharma P, Thakar A, Suman Kc S, Dhull VS, Singh H, Naswa N, et al. 68Ga-DOTANOC PET/CT for Baseline Evaluation of Patients with Head and Neck Paraganglioma. J Nucl Med. 2013;54:841–7.CrossRefPubMed

94.

Kroiss A, Shulkin BL, Uprimny C, Frech A, Gasser RW, Url C, et al. (68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT. Eur J Nucl Med Mol Imaging. 2015;42:33–41.CrossRefPubMed

95.

Sharma P, Mukherjee A, Karunanithi S, Naswa N, Kumar R, Ammini AC, et al. Accuracy of 68Ga DOTANOC PET/CT Imaging in Patients With Multiple Endocrine Neoplasia Syndromes. Clin Nucl Med. 2015;40:e351–6.CrossRefPubMed

96.

Chang CA, Pattison DA, Tothill RW, Kong G, Akhurst TJ, Hicks RJ, et al. (68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging. 2016;16:22.CrossRefPubMedPubMedCentral

97.

Han S, Suh CH, Woo S, Kim YJ, Lee JJ. Performance of (68)Ga-DOTA-Conjugated Somatostatin Receptor Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Meta-Analysis. J Nucl Med. 2019;60:369–76.CrossRefPubMed

98.

Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, et al. A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma. Eur J Nucl Med Mol Imaging. 2013;40:1800–8.CrossRefPubMed

99.

Janssen I, Blanchet EM, Adams K, Chen CC, Millo CM, Herscovitch P, et al. Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. Clin Cancer Res. 2015;21:3888–95.CrossRefPubMedPubMedCentral

100.

Janssen I, Chen CC, Zhuang Z, Millo CM, Wolf KI, Ling A, et al. Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes. J Nucl Med. 2017;58:1236–42.CrossRefPubMedPubMedCentral

101.

Taieb D, Jha A, Guerin C, Pang Y, Adams KT, Chen CC, et al. 18F-FDOPA PET/CT imaging of MAX-Related Pheochromocytoma. J Clin Endocrinol Metab. 2018;103:1574–82.CrossRefPubMedPubMedCentral

102.

Jha A, Ling A, Millo C, Gupta G, Viana B, Lin FI, et al. Superiority of (68)Ga-DOTATATE over (18)F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx )-related pheochromocytoma and paraganglioma in the pediatric population. Eur J Nucl Med Mol Imaging. 2018;45:787–97.CrossRefPubMed

103.

Kan Y, Zhang S, Wang W, Liu J, Yang J, Wang Z. (68)Ga-somatostatin receptor analogs and (18)F-FDG PET/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis. Acta Radiol. 2018;59:1466-74

104.

Gild ML, Naik N, Hoang J, Hsiao E, McGrath RT, Sywak M, et al. Role of DOTATATE-PET/CT in preoperative assessment of phaeochromocytoma and paragangliomas. Clin Endocrinol. 2018. https://doi.org/10.1111/cen.13737.

105.

Darr R, Nambuba J, Del Rivero J, Janssen I, Merino M, Todorovic M, et al. Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. Endocr Relat Cancer. 2016;23:899–908.CrossRefPubMedPubMedCentral

106.

Hentschel M, Rottenburger C, Boedeker CC, Neumann HP, Brink I. Is there an optimal scan time for 6-[F-18]fluoro-L-DOPA PET in pheochromocytomas and paragangliomas? Clin Nucl Med. 2012;37:e24–9.CrossRefPubMed

107.

Timmers HJ, Hadi M, Carrasquillo JA, Chen CC, Martiniova L, Whatley M, et al. The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med. 2007;48:1599–606.CrossRefPubMed

108.

Luxen A, Perlmutter M, Bida GT, Van Moffaert G, Cook JS, Satyamurthy N, et al. Remote, semiautomated production of 6-[18F]fluoro-L-dopa for human studies with PET. Int J Rad Appl Instrum A. 1990;41:275–81.CrossRefPubMed

109.

Namavari M, Bishop A, Satyamurthy N, Bida G, Barrio JR. Regioselective radiofluorodestannylation with [18F]F2 and [18F]CH3COOF: a high yield synthesis of 6-[18F]Fluoro-L-dopa. Int J Rad Appl Instrum A. 1992;43:989–96.CrossRefPubMed

110.

Vernaleken I, Kumakura Y, Cumming P, Buchholz HG, Siessmeier T, Stoeter P, et al. Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. Neuroimage. 2006;30:1332–9.CrossRefPubMed

111.

Garnett S, Firnau G, Nahmias C, Chirakal R. Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res. 1983;280:169–71.CrossRefPubMed

112.

Beheshti M, Pocher S, Vali R, Waldenberger P, Broinger G, Nader M, et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol. 2009;19:1425–34.CrossRefPubMed

113.

Soussan M, Nataf V, Kerrou K, Grahek D, Pascal O, Talbot JN, et al. Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. Nucl Med Commun. 2012;33:775–9.CrossRefPubMed

114.

Ginet M, Cuny T, Schmitt E, Marie PY, Verger A. 18F-FDOPA PET Imaging in Prolactinoma. Clin Nucl Med. 2017;42:e383–e4.CrossRefPubMed

115.

Berends AMA, Kerstens MN, Bolt JW, Links TP, Korpershoek E, de Krijger RR, et al. False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET ((18)F-FDOPA-PET) performed for imaging of neuroendocrine tumours. Eur J Endocrinol. 2018;179:127–35.CrossRef

116.

Treglia G, Cocciolillo F, de Waure C, Di Nardo F, Gualano MR, Castaldi P, et al. Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. Eur J Nucl Med Mol Imaging. 2012;39:1144–53.CrossRefPubMed

117.

Charrier N, Deveze A, Fakhry N, Sebag F, Morange I, Gaborit B, et al. Comparison of [(1)(1)(1)In]pentetreotide-SPECT and [(1)F]FDOPA-PET in the localization of extra-adrenal paragangliomas: the case for a patient-tailored use of nuclear imaging modalities. Clin Endocrinol. 2011;74:21–9.CrossRef

118.

Fanti S, Ambrosini V, Tomassetti P, Castellucci P, Montini G, Allegri V, et al. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Biomed Pharmacother. 2008;62:667–71.CrossRefPubMed

119.

Hoegerle S, Ghanem N, Altehoefer C, Schipper J, Brink I, Moser E, et al. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging. 2003;30:689–94.CrossRefPubMed

120.

King KS, Whatley MA, Alexopoulos DK, Reynolds JC, Chen CC, Mattox DE, et al. The use of functional imaging in a patient with head and neck paragangliomas. J Clin Endocrinol Metab. 2010;95:481–2.CrossRefPubMedPubMedCentral

121.

Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, et al. Pheochromocytomas: detection with 18F DOPA whole body PET--initial results. Radiology. 2002;222:507–12.CrossRefPubMed

122.

Imani F, Agopian VG, Auerbach MS, Walter MA, Imani F, Benz MR, et al. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med. 2009;50:513–9.CrossRefPubMed

123.

Kauhanen S, Seppanen M, Ovaska J, Minn H, Bergman J, Korsoff P, et al. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumours. Endocr Relat Cancer. 2009;16:255–65.CrossRefPubMed

124.

Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. Eur J Nucl Med Mol Imaging. 2010;37:484–93.CrossRefPubMed

125.

Rischke HC, Benz MR, Wild D, Mix M, Dumont RA, Campbell D, et al. Correlation of the Genotype of Paragangliomas and Pheochromocytomas with Their Metabolic Phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET. J Nucl Med. 2012;53:1352–8.CrossRefPubMed

126.

Nambuba J, Darr R, Janssen I, Bullova P, Adams KT, Millo C, et al. Functional imaging experience in a germline fumarate hydratase mutation–positive patient with pheochromocytoma and paraganglioma. AACE Clin Case Rep. 2016;2:e176–e81.CrossRef

127.

Burnichon N, Vescovo L, Amar L, Libe R, de Reynies A, Venisse A, et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet. 2011;20:3974–85.CrossRefPubMed

128.

Favier J, Briere JJ, Burnichon N, Riviere J, Vescovo L, Benit P, et al. The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS One. 2009;4:e7094.CrossRefPubMedPubMedCentral

129.

Lopez-Jimenez E, Gomez-Lopez G, Leandro-Garcia LJ, Munoz I, Schiavi F, Montero-Conde C, et al. Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol. 2010;24:2382–91.CrossRefPubMedPubMedCentral

130.

Pollard PJ, El-Bahrawy M, Poulsom R, Elia G, Killick P, Kelly G, et al. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J Clin Endocrinol Metab. 2006;91:4593–8.CrossRefPubMed

131.

Span PN, Rao JU, Oude Ophuis B, Lenders JW, Sweep F, Wesseling P, et al. Overexpression of the natural antisense hypoxia-inducible factor-1alpha transcript is associated with malignant phaeochromocytoma/paraganglioma. Endocr Relat Cancer. 2011.

132.

Taieb D, Sebag F, Barlier A, Tessonnier L, Palazzo FF, Morange I, et al. 18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature? J Nucl Med. 2009;50:711–7.CrossRefPubMed

133.

Garrigue P, Bodin-Hullin A, Balasse L, Fernandez S, Essamet W, Dignat-George F, et al. The Evolving Role of Succinate in Tumour Metabolism: An (18)F-FDG-Based Study. J Nucl Med. 2017;58:1749–55.CrossRefPubMedPubMedCentral

134.

Taieb D, Pacak K. New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma. Trends Endocrinol Metab. 2017;28:807–17.CrossRefPubMedPubMedCentral

135.

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.CrossRefPubMed

136.

ICRP. Radiation Dose to Patients from Radiopharmaceuticals - Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007. Ann IRCP. 2008;38:1–197.

137.

Zanotti-Fregonara P, Jan S, Taieb D, Cammilleri S, Trebossen R, Hindie E, et al. Absorbed 18F-FDG dose to the fetus during early pregnancy. J Nucl Med. 2010;51:803–5.CrossRefPubMed

138.

Zanotti-Fregonara P, Chastan M, Edet-Sanson A, Ekmekcioglu O, Erdogan EB, Hapdey S, et al. New fetal doses from 18FDG administered during pregnancy: standardization of dose calculations and estimations with voxel-based anthropomorphic phantoms. J Nucl Med. 2016;57:1760–3.CrossRefPubMed

139.

Guerin C, Pattou F, Brunaud L, Lifante JC, Mirallie E, Haissaguerre M, et al. Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study. J Clin Endocrinol Metab. 2017;102:2465–72.CrossRefPubMed

140.

Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104:700–8.CrossRefPubMedPubMedCentral

141.

Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25:2262–9.CrossRefPubMed

142.

Tiwari A, Shah N, Sarathi V, Malhotra G, Bakshi G, Prakash G, et al. Genetic status determines (18) F-FDG uptake in pheochromocytoma/paraganglioma. J Med Imaging Radiat Oncol. 2017;61:745–52.CrossRefPubMed

143.

Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychlinski C, Mather SJ, et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumours. J Nucl Med. 2003;44:708–16.PubMed

144.

Grimes J, Celler A, Birkenfeld B, Shcherbinin S, Listewnik MH, Piwowarska-Bilska H, et al. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumours. J Nucl Med. 2011;52:1474–81.CrossRefPubMed

145.

Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS. 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension. 2001;38:6–8.CrossRefPubMed

146.

Ilias I, Yu J, Carrasquillo JA, Chen CC, Eisenhofer G, Whatley M, et al. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab. 2003;88:4083–7.CrossRefPubMed

147.

Mann GN, Link JM, Pham P, Pickett CA, Byrd DR, Kinahan PE, et al. [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol. 2006;13:187–97.CrossRefPubMed

148.

Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS, et al. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med. 1992;33:1125–31.PubMed

149.

Trampal C, Engler H, Juhlin C, Bergstrom M, Langstrom B. Pheochromocytomas: detection with 11C hydroxyephedrine PET. Radiology. 2004;230:423–8.CrossRefPubMed

150.

Franzius C, Hermann K, Weckesser M, Kopka K, Juergens KU, Vormoor J, et al. Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumours of the sympathetic nervous system: feasibility study and comparison with 123I-MIBG SPECT/CT. J Nucl Med. 2006;47:1635–42.PubMed

151.

Rahbar K, Kies P, Stegger L, Juergens KU, Weckesser M. Discrepancy between glucose metabolism and sympathetic nerve terminals in a patient with metastatic paraganglioma. Eur J Nucl Med Mol Imaging. 2008;35:687.CrossRefPubMed

152.

Loc’h C, Mardon K, Valette H, Brutesco C, Merlet P, Syrota A, et al. Preparation and pharmacological characterization of [76Br]-meta-bromobenzylguanidine ([76Br]MBBG). Nucl Med Biol. 1994;21:49–55.CrossRefPubMed

153.

Vaidyanathan G, Affleck DJ, Zalutsky MR. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med. 1995;36:644–50.PubMed

154.

Yu M, Bozek J, Lamoy M, Guaraldi M, Silva P, Kagan M, et al. Evaluation of LMI1195, a novel 18F-labeled cardiac neuronal PET imaging agent, in cells and animal models. Circ Cardiovasc Imaging. 2011;4:435–43.CrossRefPubMed

155.

Pandit-Taskar N, Zanzonico P, Staton KD, Carrasquillo JA, Reidy-Lagunes D, Lyashchenko S, et al. Biodistribution and Dosimetry of (18)F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies. J Nucl Med. 2018;59:147–53.CrossRefPubMedPubMedCentral

156.

Martiniova L, Perera SM, Brouwers FM, Alesci S, Abu-Asab M, Marvelle AF, et al. Increased uptake of [(1)(2)(3)I]meta-iodobenzylguanidine, [(1)F]fluorodopamine, and [(3)H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. Endocr Relat Cancer. 2011;18:143–57.CrossRefPubMedPubMedCentral

157.

Taieb D, Neumann H, Rubello D, Al-Nahhas A, Guillet B, Hindie E. Modern nuclear imaging for paragangliomas: beyond SPECT. J Nucl Med. 2012;53:264–74.CrossRefPubMed

158.

Taieb D, Rubello D, Al-Nahhas A, Calzada M, Marzola MC, Hindie E. Modern PET imaging for paragangliomas: relation to genetic mutations. Eur J Surg Oncol. 2011;37:662–8.CrossRefPubMed

159.

Havekes B, King K, Lai EW, Romijn JA, Corssmit EP, Pacak K. New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol. 2010;72:137–45.CrossRef

160.

Taieb D, Timmers HJ, Hindie E, Guillet BA, Neumann HP, Walz MK, et al. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. E. Eur J Nucl Med Mol Imaging. 2012;39:1977–95.CrossRefPubMedPubMedCentral

161.

Hes FJ, Weiss MM, Woortman SA, de Miranda NF, van Bunderen PA, Bonsing BA, et al. Low penetrance of a SDHB mutation in a large Dutch paraganglioma family. BMC Med Genet. 2010;11:92.CrossRefPubMedPubMedCentral

162.

Schiavi F, Milne RL, Anda E, Blay P, Castellano M, Opocher G, et al. Are we overestimating the penetrance of mutations in SDHB? Hum Mutat. 2010;31:761–2.CrossRefPubMed

163.

Solis DC, Burnichon N, Timmers HJ, Raygada MJ, Kozupa A, Merino MJ, et al. Penetrance and clinical consequences of a gross SDHB deletion in a large family. Clin Genet. 2009;75:354–63.CrossRefPubMedPubMedCentral

164.

Rijken JA, Niemeijer ND, Jonker MA, Eijkelenkamp K, Jansen JC, van Berkel A, et al. The penetrance of paraganglioma and pheochromocytoma in SDHB germline mutation carriers. Clin Genet. 2018;93:60–6.CrossRefPubMed

165.

Andrews KA, Ascher DB, Pires DEV, Barnes DR, Vialard L, Casey RT, et al. Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD. J Med Genet. 2018;55:384–94.PubMed

166.

Heesterman BL, de Pont LMH, van der Mey AG, Bayley JP, Corssmit EP, Hes FJ, et al. Clinical progression and metachronous paragangliomas in a large cohort of SDHD germline variant carriers. Eur J Hum Genet. 2018;26:1339–47.CrossRefPubMedPubMedCentral

167.

Lepoutre-Lussey C, Caramella C, Bidault F, Deandreis D, Berdelou A, Al Ghuzlan A, et al. Screening in asymptomatic SDHx mutation carriers: added value of (1)(8)F-FDG PET/CT at initial diagnosis and 1-year follow-up. Eur J Nucl Med Mol Imaging. 2015;42:868–76.CrossRefPubMed

168.

Daniel E, Jones R, Bull M, Newell-Price J. Rapid-sequence MRI for long-term surveillance for paraganglioma and phaeochromocytoma in patients with succinate dehydrogenase mutations. Eur J Endocrinol. 2016;175:561–70.CrossRefPubMed

Titel: European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma
verfasst von: David Taïeb
Rodney J. Hicks
Elif Hindié
Benjamin A. Guillet
Anca Avram
Pietro Ghedini
Henri J. Timmers
Aaron T. Scott
Saeed Elojeimy
Domenico Rubello
Irène J. Virgolini
Stefano Fanti
Sona Balogova
Neeta Pandit-Taskar
Karel Pacak
Publikationsdatum: 29.06.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04398-1

Springer Medizin

Abstract

Purpose

Methods

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2019

Nigrostriatal dopamine transporter availability, and its metabolic and clinical correlates in Parkinson’s disease patients with impulse control disorders

Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [18F]MK6240 in human subjects

18F-Fluoroethyl-tyrosine uptake is correlated with amino acid transport and neovascularization in treatment-naive glioblastomas

Exceptional 4-year response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer

Prospective diagnostic performance of semiconductor SPECT myocardial perfusion imaging: wall thickening analysis reduces the need for an additional prone acquisition

[18F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer’s disease